ArticleJournal of cellular and molecular medicine2012
Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling.
Article in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The influence of selective serotonin reuptake inhibitors on stroke outcome: a systematic review and meta-analysis.Frontiers in neurology · 2026Pooled it
- Reflex vasodilation and sweating in response to passive whole body heating are blunted in women with major depressive disorder.Journal of applied physiology (Bethesda, Md. : 1985) · 2026Article
- Serotonin-modulating therapies for the management of chronic wounds.Frontiers in pharmacology · 2025Review
- Cure of Alzheimer's Dementia Requires Addressing All of the Affected Brain Cell Types.Journal of clinical medicine · 2023Article
- Supplementary Pharmacotherapy for the Behavioral Abnormalities Caused by Stressors in Humans, Focused on Post-Traumatic Stress Disorder (PTSD).Journal of clinical medicine · 2023Article
- Formulating treatment of major psychiatric disorders: algorithm targets the dominantly affected brain cell-types.Discover mental health · 2023Review
- Fluoxetine plus lithium for treatment of mental health impairment in Long Covid.Discover mental health · 2023Review
- Lessons on the Sigma-1 Receptor in TNBS-Induced Rat Colitis: Modulation of the UCHL-1, IL-6 Pathway.International journal of molecular sciences · 2020Article
- Peripheral microvascular serotoninergic signaling is dysregulated in young adults with major depressive disorder.Journal of applied physiology (Bethesda, Md. : 1985) · 2020Article
- Model Placental Barrier Phenotypic Response to Fluoxetine and Sertraline: A Comparative Study.Advanced healthcare materials · 2019Article
- Associations of Self-Reported History of Depression and Antidepressant Use Before Stroke Onset With Poststroke Post-Acute Rehabilitation Care-An Exploratory Study: The BASIC (Brain Attack Surveillance in Corpus Christi) Project.Journal of the American Heart Association · 2019Article
- Oxidative Stress Contributes to Microvascular Endothelial Dysfunction in Men and Women With Major Depressive Disorder.Circulation research · 2019Article
- Comparative Overview of the Mechanisms of Action of Hormones and Endocrine Disruptor Compounds.Toxics · 2019Review
- Fluoxetine and Raynaud's phenomenon: friend or foe?British journal of clinical pharmacology · 2017Article
- How do antidepressants influence the BOLD signal in the developing brain?Developmental cognitive neuroscience · 2017Review
- AChE and RACK1 promote the anti-inflammatory properties of fluoxetine.Journal of molecular neuroscience : MN · 2014Article
- Differential regulation of lipid metabolism genes in the brain of acetylcholinesterase knockout mice.Journal of molecular neuroscience : MN · 2014Article
- Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence.Journal of neuroinflammation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischaemic stroke patients treated with Selective Serotonin Reuptake Inhibitors (SSRI) show improved motor, cognitive and executive functions, but the underlying mechanism(s) are incompletely understood. Here, we report that cerebral arterioles in the rat brain superfused with therapeutically effective doses of the SSRI fluoxetine showed consistent, dose-dependent vasodilatation (by 1.2 to 1.6-fold), suppressible by muscarinic and nitric oxide synthase (NOS) antagonists [atropine, NG-nitro-l-arginine methyl ester (l-NAME)] but resistant to nicotinic and serotoninergic antagonists (mecamylamine, methylsergide). Fluoxetine administered 10-30 min. following experimental vascular photo-thrombosis increased arterial diameter (1.3-1.6), inducing partial, but lasting reperfusion of the ischaemic brain. In brain endothelial b.End.3 cells, fluoxetine induced rapid muscarinic receptor-dependent increases in intracellular [Ca(2+) ] and promoted albumin- and eNOS-dependent nitric oxide (NO) production and HSP90 interaction. In vitro, fluoxetine suppressed recombinant human acetylcholinesterase (rhAChE) activity only in the presence of albumin. That fluoxetine induces vasodilatation of cerebral arterioles suggests co-promotion of endothelial muscarinic and nitric oxide signalling, facilitated by albumin-dependent inhibition of serum AChE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.